MIB‐1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy

The MIB‐1 labeling index, which is based on Ki67 immunostaining, is widely used to evaluate the proliferation of tumor cells in lymphoma. However, its clinical significance has not been fully assessed. We retrospectively evaluated the prognostic impact of the MIB‐1 labeling index at the time of diag...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Sci
Auteurs principaux: Yamamoto, Eri, Tomita, Naoto, Sakata, Seiji, Tsuyama, Naoko, Takeuchi, Kengo, Nakajima, Yuki, Miyashita, Kazuho, Tachibana, Takayoshi, Takasaki, Hirotaka, Tanaka, Masatsugu, Hashimoto, Chizuko, Koharazawa, Hideyuki, Fujimaki, Katsumichi, Taguchi, Jun, Harano, Hiroshi, Motomura, Shigeki, Ishigatsubo, Yoshiaki
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2013
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7653523/
https://ncbi.nlm.nih.gov/pubmed/24112697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12288
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires